Teva files Form 144 for proposed sale of ordinary shares

Teva Pharmaceutical Industries Limited filed a Form 144 reporting proposed sales of ordinary shares.

Accepted by SEC EDGAR 02/26/2026 - 04:11 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited filed a Form 144 reporting proposed sales of ordinary shares. The filing lists proposed dispositions including 182,454 shares and 52,320 shares as examples, with the notice dated 02/26/2026. The entries are described as "shares from rollover" and "compensation" in the filing.

Insights

Securities Counsel

Form 144 lists proposed dispositions by an affiliate; timing and proceeds depend on brokered transactions.

The filing enumerates specific proposed sales, including 182,454 shares and 52,320 shares, and records the filing date as 02/26/2026. It identifies the nature of the shares as shares from rollover and compensation.

Actual sale execution, timing, and cash‑flow treatment are governed by brokerage procedures and any applicable resale rules; subsequent Form 4/Form 5 or trade reports will show completed transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001798443
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Kalif Eliyahu Sharon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EVP CHIEF FINANCIAL OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	345810	11634702.06	1149812898	02/26/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	02/28/2023	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			12309	02/26/2026	COMPENSATION
ORDINARY SHARES	03/04/2024	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			27537	02/26/2026	COMPENSATION
ORDINARY SHARES	03/05/2024	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			52320	02/26/2026	COMPENSATION
ORDINARY SHARES	03/03/2025	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			49800	02/26/2026	COMPENSATION
ORDINARY SHARES	03/04/2025	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			182454	02/26/2026	COMPENSATION
ORDINARY SHARES	03/05/2025	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			21390	02/26/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SHARES WERE SOLD PURSUANT TO COMPLY WITH RULE 10B51 C FROM A PLAN DATED NOVEMBER 26 2025
Date of Notice	02/26/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)